Global Markets Direct’s, ‘Cardiomyopathy – Pipeline Review, H2 2015′, provides an overview of the Cardiomyopathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Cardiomyopathy
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Cardiomyopathy pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cardiomyopathy Overview 9
Therapeutics Development 10
Pipeline Products for Cardiomyopathy - Overview 10
Pipeline Products for Cardiomyopathy - Comparative Analysis 11
Cardiomyopathy - Therapeutics under Development by Companies 12
Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 14
Cardiomyopathy - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Cardiomyopathy - Products under Development by Companies 18
Cardiomyopathy - Products under Investigation by Universities/Institutes 19
Cardiomyopathy - Companies Involved in Therapeutics Development 20
Array BioPharma Inc. 20
Bioheart, Inc. 21
Gilead Sciences, Inc. 22
Heart Metabolics Limited 23
Hemostemix Ltd 24
Kasiak Research Private Limited 25
miRagen Therapeutics, Inc. 26
MyoKardia, Inc. 27
Neurimmune Holding AG 28
Nyken BV 29
Sanofi 30
Shire Plc 31
Stemedica Cell Technologies, Inc. 32
Stempeutics Research Private Limited 33
Torrent Pharmaceuticals Limited 34
Vericel Corporation 35
Virocan Therapeutics Private Limited 36
Cardiomyopathy - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ACP-01 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AdipoCell - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AmVidcm-008 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ARRY-797 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
binimetinib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CAP-1002 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cyndacel-M - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs for Dilated Cardiomyopathy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
eleclazine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Gene Therapy for Cardiomyopathy - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ixmyelocel-T - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
JR-100 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Mesenchymal Stem Cells - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MGN-9103 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MYK-461 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
NI-301 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NYK-1112 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
perhexiline maleate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Recombinant Peptide to Agonize GLP-1 for Cardiomyopathy - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Recombinat Proten to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Refacell-DCM - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SHP-627 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecule for Dilated Cardiomyopathy - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Stempeucel - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TRC-120038 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
YS-1402 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Cardiomyopathy - Recent Pipeline Updates 90
Cardiomyopathy - Dormant Projects 110
Cardiomyopathy - Dormant Projects 110
Cardiomyopathy - Discontinued Products 111
Cardiomyopathy - Product Development Milestones 112
Featured News & Press Releases 112
Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy 112
Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy 112
Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 113
Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy 113
Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan 114
Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy 114
Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure 115
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 116
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 116
Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada 117
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 118
Disclaimer 119

List of Tables

Number of Products under Development for Cardiomyopathy, H2 2015 10
Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Comparative Analysis by Unknown Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Investigation by Universities/Institutes, H2 2015 19
Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2015 20
Cardiomyopathy - Pipeline by Bioheart, Inc., H2 2015 21
Cardiomyopathy - Pipeline by Gilead Sciences, Inc., H2 2015 22
Cardiomyopathy - Pipeline by Heart Metabolics Limited, H2 2015 23
Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2015 24
Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2015 25
Cardiomyopathy - Pipeline by miRagen Therapeutics, Inc., H2 2015 26
Cardiomyopathy - Pipeline by MyoKardia, Inc., H2 2015 27
Cardiomyopathy - Pipeline by Neurimmune Holding AG, H2 2015 28
Cardiomyopathy - Pipeline by Nyken BV, H2 2015 29
Cardiomyopathy - Pipeline by Sanofi, H2 2015 30
Cardiomyopathy - Pipeline by Shire Plc, H2 2015 31
Cardiomyopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2015 32
Cardiomyopathy - Pipeline by Stempeutics Research Private Limited, H2 2015 33
Cardiomyopathy - Pipeline by Torrent Pharmaceuticals Limited, H2 2015 34
Cardiomyopathy - Pipeline by Vericel Corporation, H2 2015 35
Cardiomyopathy - Pipeline by Virocan Therapeutics Private Limited, H2 2015 36
Assessment by Monotherapy Products, H2 2015 37
Number of Products by Stage and Target, H2 2015 39
Number of Products by Stage and Mechanism of Action, H2 2015 41
Number of Products by Stage and Route of Administration, H2 2015 43
Number of Products by Stage and Molecule Type, H2 2015 45
Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2015 90
Cardiomyopathy - Dormant Projects, H2 2015 110
Cardiomyopathy - Discontinued Products, H2 2015 111

List of Figures

Number of Products under Development for Cardiomyopathy, H2 2015 10
Number of Products under Development for Cardiomyopathy - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Products, H2 2015 16
Assessment by Monotherapy Products, H2 2015 37
Number of Products by Top 10 Targets, H2 2015 38
Number of Products by Stage and Top 10 Targets, H2 2015 38
Number of Products by Top 10 Mechanism of Actions, H2 2015 40
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 40
Number of Products by Top 10 Routes of Administration, H2 2015 42
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 42
Number of Products by Top 10 Molecule Types, H2 2015 44
Number of Products by Stage and Top 10 Molecule Types, H2 2015 44